Brokerages Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Price Target at $16.29

Key Points

• COMPASS Pathways PLC has received a consensus rating of "Moderate Buy" from analysts, with six out of seven brokers recommending a buy and one recommending a hold.
• The average 12-month price target for COMPASS Pathways is $16.29, although recent price targets vary significantly among analysts, ranging from $6.00 to $45.00.
• COMPASS Pathways reported earnings of ($0.38) per share for the last quarter, missing analyst expectations by $0.01, and is projected to post an annual EPS of (-2.33) this year.

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $16.2857.

CMPS has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $12.00 target price on shares of COMPASS Pathways in a report on Tuesday, May 27th. Evercore ISI reaffirmed an "in-line" rating and issued a $6.00 price target (down from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. HC Wainwright lowered their price target on COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating for the company in a report on Monday, August 4th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 price target on shares of COMPASS Pathways in a report on Friday, August 1st.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in COMPASS Pathways by 161.3% during the fourth quarter. Renaissance Technologies LLC now owns 212,700 shares of the company's stock worth $804,000 after buying an additional 131,300 shares during the period. Barclays PLC boosted its stake in COMPASS Pathways by 2.1% during the 4th quarter. Barclays PLC now owns 419,194 shares of the company's stock worth $1,585,000 after purchasing an additional 8,718 shares during the period. Marshall Wace LLP acquired a new stake in COMPASS Pathways during the 4th quarter worth $1,395,000. Two Sigma Securities LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth $135,000. Finally, Virtus ETF Advisers LLC boosted its stake in COMPASS Pathways by 21.4% during the 4th quarter. Virtus ETF Advisers LLC now owns 16,121 shares of the company's stock worth $61,000 after purchasing an additional 2,840 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Stock Down 8.1%

Shares of CMPS stock traded down $0.39 during trading on Wednesday, reaching $4.42. The company's stock had a trading volume of 1,548,913 shares, compared to its average volume of 1,639,147. The stock's 50-day moving average price is $3.95 and its 200 day moving average price is $3.85. The company has a market capitalization of $424.05 million, a price-to-earnings ratio of -2.40 and a beta of 2.17. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.08. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.